Analytical Data
-
基因名
HLA-E*01:03&B2M&CMV UL40(VMAPRTVIL) Monomer
- Application
-
别名
HLA-E*0103 & B2M & CMV UL40 (VMAPRTVIL)
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P13747 (G22-I305)&P61769
-
表达区间
P13747 (G22-I305)&P61769 (I21-M119)&VMAPRTVIL
-
分子量
40-43 kDa and 12 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The HLA-E*01:03/B2M/CMV UL40 (VMAPRTVIL) monomer is a recombinant protein that is critical for understanding immune responses mediated by the major histocompatibility complex (MHC) class I. HLA-E is a non-classical MHC molecule that plays a vital role in immune regulation by presenting peptides from the UL40 protein of cytomegalovirus (CMV) to natural killer (NK) cells. The peptide VMAPRTVIL, derived from CMV, effectively binds to HLA-E, enabling the recognition and modulation of NK cell activity. Research on this specific recombinant protein is essential for clarifying how HLA-E interacts with both the innate and adaptive immune systems, particularly in the context of viral infections and potential therapeutic applications. Understanding this interaction can provide insights into immune evasion strategies employed by pathogens and contribute to the development of new immunotherapeutic approaches, especially in the context of diseases such as CMV infections, cancer, and transplantation. Thus, the study of the HLA-E*01:03/B2M/CMV UL40 monomer combines molecular biology, immunology, and virology, making it an important focus for advancing our knowledge of immune responses and for potential clinical applications.
